Headlines about Novadaq Technologies (NASDAQ:NVDQ) (TSE:NDQ) have trended positive on Saturday, according to Alpha One. The research firm, a subsidiary of Accern, identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Novadaq Technologies earned a daily sentiment score of 0.31 on Alpha One’s scale. Alpha One also assigned headlines about the medical research company an impact score of 100 out of 100, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the next several days.
Novadaq Technologies (NASDAQ:NVDQ) opened at 7.24 on Friday. The stock’s market cap is $418.49 million. Novadaq Technologies has a 12-month low of $6.00 and a 12-month high of $12.74. The firm’s 50 day moving average price is $7.40 and its 200-day moving average price is $7.50.
Novadaq Technologies (NASDAQ:NVDQ) last issued its earnings results on Wednesday, May 3rd. The medical research company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.03. The company had revenue of $21.08 million for the quarter, compared to analysts’ expectations of $20.12 million. Novadaq Technologies had a negative return on equity of 31.34% and a negative net margin of 55.26%. Equities research analysts anticipate that Novadaq Technologies will post ($0.80) earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on NVDQ shares. Canaccord Genuity reissued a “buy” rating and issued a $10.00 target price on shares of Novadaq Technologies in a research note on Monday, February 6th. Royal Bank of Canada set a $12.00 price target on Novadaq Technologies and gave the company a “buy” rating in a report on Wednesday, March 1st. Scotiabank restated an “outperform” rating and set a $18.00 price target on shares of Novadaq Technologies in a report on Thursday, May 4th. Stifel Nicolaus reduced their price target on Novadaq Technologies from $16.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, March 1st. Finally, Feltl & Co. downgraded Novadaq Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, March 1st. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Novadaq Technologies has an average rating of “Buy” and a consensus target price of $11.25.
About Novadaq Technologies
NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.
Receive News & Ratings for Novadaq Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.